Metabolic & Weight Management

Mazdutide

Also known as IBI362 · LY3305677

Clinically studiedSubcutaneous injectionApproved by China's NMPA in 2025 for chronic weight management and for glycemic control in type 2 diabetes (developed by Innovent Biologics under license from Eli Lilly). Not approved by the U.S. FDA; it remains investigational in the United States and is not an approved compound for U.S. pharmacy compounding under 503A/503B. For athletes, GLP-1 and glucagon receptor agonists are not on the WADA Prohibited List; WADA has added certain GLP-1 receptor agonists (for example semaglutide and tirzepatide) to its 2026 Monitoring Program, meaning such use is observed rather than banned. Mazdutide is not itself named on that program.

Mazdutide is a synthetic peptide analog of oxyntomodulin, a gut hormone, engineered to activate both the GLP-1 and glucagon receptors. Through GLP-1 receptor activation it is associated in research with promoting insulin secretion, lowering blood glucose, and reducing appetite, while glucagon receptor activation is proposed to additionally increase energy expenditure and influence hepatic fat metabolism. It was developed by Innovent Biologics under license from Eli Lilly and reached late-stage human trials, with China's NMPA approving it in 2025 for chronic weight management and, subsequently, for glycemic control in type 2 diabetes. As an approved drug (in China) supported by multiple completed and ongoing Phase 3 programs (the GLORY and DREAMS series), it has a substantial human clinical research base, though it remains investigational in the United States and is not FDA-approved.

Studied / used for

Investigated for chronic weight management in adults with overweight or obesity
Studied for glycemic control in adults with type 2 diabetes
Investigated for metabolic dysfunction-associated steatohepatitis (MASH), within the broader MASLD (formerly NAFLD) category
Studied for obstructive sleep apnea in people with obesity
Investigated for cardiometabolic measures such as waist circumference reduction

Commonly reported side effects

Commonly reported gastrointestinal effects such as nausea
Commonly reported diarrhea
Commonly reported vomiting
Commonly reported decreased appetite
Reports of injection-site reactions

Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds